We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ultragenyx

News List

n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases americanpharmaceuticalreview
April 07, 2021
n-Lorem Foundation announced a new partnership with Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx biospace
December 20, 2017
Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc.The PRV is for rare pediatric diseases.
M&As this week: Catalent, Ultragenyx Pharmaceutical pharmaceufical-technology
September 25, 2017
The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.
Phase 3 fail prompts Ultragenyx to can muscle disease drug fiercebiotech
August 24, 2017
A phase 3 fail wiped more than 10% off Ultragenyx's share price.
Ultragenyx stumbles in P3 trial for severe muscle disease pharmafile
August 23, 2017
Ultragenyx has revealed results from a Phase 3 trial into the treatment of GNE myopathy showed that its compound did not successfully meet the primary or secondary endpoints of the study.